Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIODESIX INCBDSX · Entity 6053 | Chief Accounting Officer | February 20, 2026 | February 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIODESIX INC
Report date February 20, 2026 · Filed February 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,586 |
Ending reported balance
After 2026-02-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-20 · Exercise / conversion · Acquired 563 · Balance 1,797 F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Row 2 · 2026-02-23 · Sale · Disposed 211 · Balance 1,586 F2: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F3: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $12.58 to $13.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,689 |
Reported balance
After 2026-02-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-20 · Exercise / conversion · Disposed 563 · Balance 1,689 F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. F5: These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.
F3: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $12.58 to $13.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.
F5: These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 23, 2026 Filed Feb 24, 2026 01:22 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 211 | $12.78 | $2,695.65 |
DisclosureSEC source: 0000905148-26-000990 · form4.xml · nonDerivative · entry 2 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,586 F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $12.58 to $13.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 01:22 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 563 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-000990 · form4.xml · derivative · entry 3 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,689 Underlying: Common Stock · 563 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · shares: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. F5 · derivative.exercise_date: These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F5 · derivative.expiration_date: These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F4 · derivative.underlying_shares: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. F4 · balance_after: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 01:22 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 563 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-26-000990 · form4.xml · nonDerivative · entry 1 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,797 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| February 10, 2026 Filed Feb 11, 2026 23:03 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 101 | $10.08 | $1,018.49 |
DisclosureSEC source: 0000905148-26-000636 · form4.xml · nonDerivative · entry 2 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,234 F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $9.94 to $10.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 23:03 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 235 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-000636 · form4.xml · derivative · entry 4 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234 Underlying: Common Stock · 235 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · shares: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. F6 · derivative.exercise_date: These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F6 · derivative.expiration_date: These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F5 · derivative.underlying_shares: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. F5 · balance_after: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 23:03 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 28 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-000636 · form4.xml · derivative · entry 3 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: These RSUs vested in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and had no expiration date. F4 · derivative.expiration_date: These RSUs vested in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and had no expiration date. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 23:03 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 263 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-26-000636 · form4.xml · nonDerivative · entry 1 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 16, 2026 Filed Jan 20, 2026 21:22 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 83 | $8.15 | $676.39 |
DisclosureSEC source: 0000905148-26-000253 · form4.xml · nonDerivative · entry 2 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,072 F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $8.10 to $8.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 15, 2026 Filed Jan 20, 2026 21:22 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 219 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-000253 · form4.xml · derivative · entry 3 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 436 Underlying: Common Stock · 219 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · shares: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. F5 · derivative.exercise_date: These RSUs vest in a series of four successive equal annual installments measured from January 15, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F5 · derivative.expiration_date: These RSUs vest in a series of four successive equal annual installments measured from January 15, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F4 · derivative.underlying_shares: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. F4 · balance_after: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. Read SEC document |
| January 15, 2026 Filed Jan 20, 2026 21:22 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 219 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-26-000253 · form4.xml · nonDerivative · entry 1 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,155 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:24 UTC | BIODESIX INC BDSX · Entity 6053 | GrantStock Options (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $6.46 | $0.00 |
DisclosureSEC source: 0000905148-26-000064 · form4.xml · derivative · entry 1 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2036-01-01 F1 · derivative.exercise_date: This option vests in a series of forty-eight successive equal monthly installments measured from January 2, 2026, generally subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| November 10, 2025 Filed Nov 13, 2025 21:54 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 31 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-003933 · form4.xml · derivative · entry 3 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29 Underlying: Common Stock · 31 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1 · shares: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. F4 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F4 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F1 · derivative.underlying_shares: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. F1 · balance_after: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. Read SEC document |
| November 10, 2025 Filed Nov 13, 2025 21:54 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 13 | $7.62 | $99.06 |
DisclosureSEC source: 0000905148-25-003933 · form4.xml · nonDerivative · entry 2 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 936 F3 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. Read SEC document |
| November 10, 2025 Filed Nov 13, 2025 21:54 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 31 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-25-003933 · form4.xml · nonDerivative · entry 1 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 949 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. F2 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1 · balance_after: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. Read SEC document |
| August 13, 2025 Filed Aug 14, 2025 21:24 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 228 | $0.42 | $94.92 |
DisclosureSEC source: 0000905148-25-002980 · form4.xml · nonDerivative · entry 2 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,375 F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $0.4076 to $0.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 21:24 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 602 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-002980 · form4.xml · derivative · entry 3 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,203 Underlying: Common Stock · 602 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F4 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 21:24 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 602 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-25-002980 · form4.xml · nonDerivative · entry 1 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,603 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 13, 2025 Filed May 13, 2025 22:36 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 112 | $0.35 | $39.52 |
DisclosureSEC source: 0000905148-25-001609 · form4.xml · nonDerivative · entry 3 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,001 F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F4 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $0.3395 to $0.3622, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 12, 2025 Filed May 13, 2025 22:36 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 112 | $0.36 | $40.25 |
DisclosureSEC source: 0000905148-25-001609 · form4.xml · nonDerivative · entry 2 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,113 F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $0.3431 to $0.4014, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 09, 2025 Filed May 13, 2025 22:36 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 602 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-001609 · form4.xml · derivative · entry 4 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,805 Underlying: Common Stock · 602 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F5 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document |
| May 09, 2025 Filed May 13, 2025 22:36 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 602 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-25-001609 · form4.xml · nonDerivative · entry 1 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| February 20, 2025 Filed Feb 26, 2025 21:32 UTC | BIODESIX INC BDSX · Entity 6053 | GrantStock Options (Right to buy) · Derivative | 39,664 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0000905148-25-000782 · form4.xml · derivative · entry 3 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,664 Underlying: Common Stock · 39,664 shares Expires 2035-02-19 F4 · derivative.exercise_date: This option vested in full on February 20, 2025. Under the Issuer's 2024 Bonus-to-Options Program, the Reporting Person elected to receive a portion of the annual cash bonus earned during 2024 in the form of a fully-vested option. Read SEC document |
| February 20, 2025 Filed Feb 26, 2025 21:32 UTC | BIODESIX INC BDSX · Entity 6053 | GrantStock Options (Right to buy) · Derivative | 90,100 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0000905148-25-000782 · form4.xml · derivative · entry 2 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,100 Underlying: Common Stock · 90,100 shares Expires 2035-02-19 F3 · derivative.exercise_date: This option vests in a series of forty-eight successive equal monthly installments measured from February 20, 2025, generally subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| February 20, 2025 Filed Feb 26, 2025 21:32 UTC | BIODESIX INC BDSX · Entity 6053 | GrantRestricted Stock Units · Derivative | 45,050 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000782 · form4.xml · derivative · entry 1 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,050 Underlying: Common Stock · 45,050 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F2 · derivative.expiration_date: These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document |
| February 11, 2025 Filed Feb 12, 2025 22:12 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 3,630 | $0.92 | $3,354.85 |
DisclosureSEC source: 0000905148-25-000528 · form4.xml · nonDerivative · entry 2 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,623 F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $0.90 to $0.9536, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 22:12 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 4,371 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000528 · form4.xml · derivative · entry 5 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,112 Underlying: Common Stock · 4,371 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: These RSUs vest in a series of four successive equal annual installments measured from January 15, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F6 · derivative.expiration_date: These RSUs vest in a series of four successive equal annual installments measured from January 15, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 22:12 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 4,694 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000528 · form4.xml · derivative · entry 4 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,388 Underlying: Common Stock · 4,694 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F5 · derivative.expiration_date: These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 22:12 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 601 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000528 · form4.xml · derivative · entry 3 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,407 Underlying: Common Stock · 601 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F4 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 22:12 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 9,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-25-000528 · form4.xml · nonDerivative · entry 1 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| November 12, 2024 Filed Nov 13, 2024 21:22 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 98 | $1.40 | $137.28 |
DisclosureSEC source: 0000905148-24-003059 · form4.xml · nonDerivative · entry 3 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,587 F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F4 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.39 to $1.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 11, 2024 Filed Nov 13, 2024 21:22 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 105 | $1.39 | $146.04 |
DisclosureSEC source: 0000905148-24-003059 · form4.xml · nonDerivative · entry 2 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,685 F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.36 to $1.42, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 08, 2024 Filed Nov 13, 2024 21:22 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 602 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-003059 · form4.xml · derivative · entry 4 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,008 Underlying: Common Stock · 602 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F5 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document |
| November 08, 2024 Filed Nov 13, 2024 21:22 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 602 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-24-003059 · form4.xml · nonDerivative · entry 1 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| August 12, 2024 Filed Aug 12, 2024 23:24 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 54 | $1.57 | $84.88 |
DisclosureSEC source: 0000905148-24-002116 · form4.xml · nonDerivative · entry 3 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,188 F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F4 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.52 to $1.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 09, 2024 Filed Aug 12, 2024 23:24 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 155 | $1.60 | $248.16 |
DisclosureSEC source: 0000905148-24-002116 · form4.xml · nonDerivative · entry 2 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,242 F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.57 to $1.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 08, 2024 Filed Aug 12, 2024 23:24 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 602 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-002116 · form4.xml · derivative · entry 4 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,610 Underlying: Common Stock · 602 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F5 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document |
| August 08, 2024 Filed Aug 12, 2024 23:24 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 602 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-24-002116 · form4.xml · nonDerivative · entry 1 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,397 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 23, 2024 Filed May 23, 2024 23:15 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionSeries A Non-Voting Convertible Preferred Stock · Derivative | 22 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-001616 · form4.xml · derivative · entry 2 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 880 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's stockholders approved the conversion of shares of the Issuer's Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") into shares of the Issuer's common stock ("Common Stock") at its 2024 annual meeting of stockholders held on May 21, 2024, after which each share of Preferred Stock automatically converted into 40 shares of Common Stock on May 23, 2024. F1 · derivative.exercise_date: The Issuer's stockholders approved the conversion of shares of the Issuer's Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") into shares of the Issuer's common stock ("Common Stock") at its 2024 annual meeting of stockholders held on May 21, 2024, after which each share of Preferred Stock automatically converted into 40 shares of Common Stock on May 23, 2024. F1 · derivative.expiration_date: The Issuer's stockholders approved the conversion of shares of the Issuer's Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") into shares of the Issuer's common stock ("Common Stock") at its 2024 annual meeting of stockholders held on May 21, 2024, after which each share of Preferred Stock automatically converted into 40 shares of Common Stock on May 23, 2024. Read SEC document |
| May 23, 2024 Filed May 23, 2024 23:15 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 880 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-24-001616 · form4.xml · nonDerivative · entry 1 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Issuer's stockholders approved the conversion of shares of the Issuer's Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") into shares of the Issuer's common stock ("Common Stock") at its 2024 annual meeting of stockholders held on May 21, 2024, after which each share of Preferred Stock automatically converted into 40 shares of Common Stock on May 23, 2024. Read SEC document |
| May 09, 2024 Filed May 10, 2024 21:06 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 244 | $1.48 | $361.00 |
DisclosureSEC source: 0000905148-24-001355 · form4.xml · nonDerivative · entry 2 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,915 F3 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F4 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.43 to $1.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 08, 2024 Filed May 10, 2024 21:06 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 601 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-001355 · form4.xml · derivative · entry 3 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,212 Underlying: Common Stock · 601 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F5 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document |
| May 08, 2024 Filed May 10, 2024 21:06 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 601 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-24-001355 · form4.xml · nonDerivative · entry 1 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,159 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · balance_after: Includes an aggregate 10 shares that were inadvertently reported as being sold on February 9 and February 12, 2024 in the Form 4 filed by the Reporting Person on February 12, 2024. Read SEC document |
| April 05, 2024 Filed Apr 9, 2024 23:36 UTC | BIODESIX INC BDSX · Entity 6053 | GrantSeries A Non-Voting Convertible Preferred Stock · Derivative | 22 | $46.00 | $1,012.00 |
DisclosureSEC source: 0000905148-24-001144 · form4.xml · derivative · entry 1 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22 Underlying: Common Stock · 880 shares Expires not disclosed F1 · derivative.exercise_price: These shares of Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") were issued to the Reporting Person under securities purchase agreements entered into with the Issuer, pursuant to which the Issuer has agreed to submit to its stockholders the approval of the conversion of the Preferred Stock into shares of Common Stock at its 2024 annual meeting of stockholders (the "Conversion Proposal"). Following such approval of the Conversion Proposal, each share of Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that the Reporting Person is prohibited from converting shares of Preferred Stock into shares of Common Stock if, as a result of such conversion, the Reporting Person, together with his affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Preferred Stock has no expiration date. F1 · price: These shares of Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") were issued to the Reporting Person under securities purchase agreements entered into with the Issuer, pursuant to which the Issuer has agreed to submit to its stockholders the approval of the conversion of the Preferred Stock into shares of Common Stock at its 2024 annual meeting of stockholders (the "Conversion Proposal"). Following such approval of the Conversion Proposal, each share of Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that the Reporting Person is prohibited from converting shares of Preferred Stock into shares of Common Stock if, as a result of such conversion, the Reporting Person, together with his affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Preferred Stock has no expiration date. F1 · derivative.exercise_date: These shares of Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") were issued to the Reporting Person under securities purchase agreements entered into with the Issuer, pursuant to which the Issuer has agreed to submit to its stockholders the approval of the conversion of the Preferred Stock into shares of Common Stock at its 2024 annual meeting of stockholders (the "Conversion Proposal"). Following such approval of the Conversion Proposal, each share of Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that the Reporting Person is prohibited from converting shares of Preferred Stock into shares of Common Stock if, as a result of such conversion, the Reporting Person, together with his affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Preferred Stock has no expiration date. F1 · derivative.expiration_date: These shares of Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") were issued to the Reporting Person under securities purchase agreements entered into with the Issuer, pursuant to which the Issuer has agreed to submit to its stockholders the approval of the conversion of the Preferred Stock into shares of Common Stock at its 2024 annual meeting of stockholders (the "Conversion Proposal"). Following such approval of the Conversion Proposal, each share of Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that the Reporting Person is prohibited from converting shares of Preferred Stock into shares of Common Stock if, as a result of such conversion, the Reporting Person, together with his affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Preferred Stock has no expiration date. Read SEC document |
| February 21, 2024 Filed Feb 29, 2024 23:17 UTC | BIODESIX INC BDSX · Entity 6053 | GrantStock Options (Right to buy) · Derivative | 14,280 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0000905148-24-000826 · form4.xml · derivative · entry 1 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,280 Underlying: Common Stock · 14,280 shares Expires 2034-02-20 F1 · derivative.exercise_date: This option vested in full on February 21, 2024. Under the Issuer's 2023 Bonus-to-Options Program, the Reporting Person elected to receive a portion of the annual cash bonus earned during 2023 in the form of a fully-vested option. Read SEC document |
| February 12, 2024 Filed Feb 13, 2024 02:46 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 922 | $1.66 | $1,534.85 |
DisclosureSEC source: 0000905148-24-000587 · form4.xml · nonDerivative · entry 3 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,548 F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F4 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.55 to $1.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 02:46 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 1,077 | $1.92 | $2,064.18 |
DisclosureSEC source: 0000905148-24-000587 · form4.xml · nonDerivative · entry 2 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,470 F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.8191 to $2.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 02:46 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 4,694 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-000587 · form4.xml · derivative · entry 7 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,082 Underlying: Common Stock · 4,694 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F8 · derivative.exercise_date: These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F8 · derivative.expiration_date: These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 02:46 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 602 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-000587 · form4.xml · derivative · entry 6 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,813 Underlying: Common Stock · 602 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F7 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F7 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 02:46 UTC | BIODESIX INC BDSX · Entity 6053 | GrantStock Options (Right to buy) · Derivative | 34,966 | $0.00 Strike: $1.99 | $0.00 |
DisclosureSEC source: 0000905148-24-000587 · form4.xml · derivative · entry 5 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,966 Underlying: Common Stock · 34,966 shares Expires 2034-02-07 F6 · derivative.exercise_date: This option vests in a series of forty-eight successive equal monthly installments measured from January 15, 2024, generally subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 02:46 UTC | BIODESIX INC BDSX · Entity 6053 | GrantRestricted Stock Units · Derivative | 17,483 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-000587 · form4.xml · derivative · entry 4 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,483 Underlying: Common Stock · 17,483 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: These RSUs vest in a series of four successive equal annual installments measured from January 15, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F5 · derivative.expiration_date: These RSUs vest in a series of four successive equal annual installments measured from January 15, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.